Man Develops Bladder Cancer After Taking Zantac for Over a Decade
After taking the heartburn drug Zantac and its generic equivalents for a decade, a man from Washington State claims he developed bladder cancer.
Zantac (ranitidine) lawsuit alleges that the acid-reducing drug contains unsafe amounts of NDMA—a cancer-causing compound—and that people who took the drug developed cancer.
Cancers below were diagnosed among those who filed litigation:
- Bladder cancer
- Stomach cancer
- Liver cancer
- Kidney cancer
- Prostate cancer
- Colon cancer
- Breast cancer
Plaintiff Christopher Miller, and his wife, Ashley Miller, of Shelton, Washington, say that he was diagnosed with bladder cancer in July 2020 in the Zantac case, which was filed in the Southern District of Florida on March 29.
This diagnosis came several months after he started taking ranitidine at the time of the voluntary recalls in October 2019. In the Zantac Cancer lawsuit, Miller said that he had been taking ranitidine since November 2009.
The plaintiff says he sustained severe injuries after taking Zantac (ranitidine) for years in a recent Zantac case brought in the United States District Court for the Southern District of Florida.
He accuses the acid-reducing drug’s makers of failing to warn about the dangers it poses, especially the fact that it contains N-nitrosodimethylamine (NDMA), a possible human carcinogen.
Miller’s wife, Ashley, claimed the loss of benefits of a family relationship due to the drug companies’ conduct in the same Zantac case.
Several manufacturers voluntarily recalled Zantac and generic ranitidine near the end of 2019 after the medication was linked to N-Nitrosodimethylamine (NDMA), a suspected human carcinogen.
The FDA ordered that all ranitidine drugs be taken off the market a few months later, in April 2020, and hundreds of Zantac cases have been filed against companies that manufacture ranitidine.
There have been so many lawsuits filed that, in February 2020, multidistrict litigation (MDL) was created, transferring all Zantac cancer lawsuits filed in federal court to the United States District Court for the Southern District of Florida.
Dismissal of the Claims
In December, a federal judge in Florida rejected state allegations in the multidistrict lawsuit, finding that federal law preempts the labeling and misbranding claims asserted in the class actions.
Still, plaintiffs were given another opportunity to pursue the case. This means that, in order to comply with state law, the manufacturers will have first to obtain FDA approval to make certain changes.
Plaintiffs argued that federal law should not preempt their state law claims because they were worried about the drug’s misbranding at the time it was marketed, as well as the manufacturers’ failure to advise or take other steps that could have been taken while still complying with federal law.
Despite the plaintiffs’ misbranding statement, the judge ruled in December that the arguments for design flaw and failure to alert, as well as the product and mislabeling claims, should be preempted.
Other claims raised about expiration dates, as well as concerns about the tainted drug’s storage, testing, and transportation conditions, were permitted to be re-filed by the judge.
In addition to manufacturing fault claims and Magnuson-Moss Warranty Act breach claims, the order granted plaintiffs leave to refile charges that the manufacturers should have warned the FDA of risks.
Editor’s Note on Zantac Cancer Class Action Lawsuit:
This article is published to inform you of the latest lawsuit filed against Zantac and its eventual dismissal.
What are your thoughts on this piece? Do you know someone who uses Zantac? If so, please send us a message by clicking the ‘Contact Us’ button below. We’d love to hear your thoughts.
Suggested Article: Lawsuit Investigation Over Zantac…